We’ve detected you are on Internet Explorer. For the best Barrons.com experience, please update to a modern browser. We’ve detected you are on Internet Explorer. For the best Barrons.com e...
Tag: MRK
It’s Pharma Time: Why Merck and Lilly Stock Are Buys, but not Pfizer.
My 2023 biotech outlook calls for continued momentum in name changes. I just need to figure out what the stocks will do. Last year, Respira Technologies became Qnovia. It’s run by a former tobacco exe...
BioNTech upgraded to buy on high hopes for combined flu/COVID vaccine and oncology pipeline
Bank of America analysts upgraded BioNTech SE stock to buy from hold on Thursday, citing excitement about its mRNA technology and the outlook for a combined flu/COVID vaccine and oncology vaccines tha...
Dow on verge of a ‘golden cross,’ even as BlackRock predicts historic recession
Despite worries about inflation and an impending recession, there is at least one sign that some bullish market technical analysts might latch onto. An upbeat golden cross appears to be forming in the...
Maker Price Prediction: MRK Fluctuates in Tight Range, What’s Next Step?
Maker Token has been witnessing a range-bound market for the past two weeks. On the 4-hours chart, MKR price remained well above the 20,50 and 100 simple moving averages. Speculators saw a decrease in...
Stock Market Looks Poised to Rally as Bond Yield Falls
Text size Michael Nagle/Bloomberg The worst may be over for the stock market. Key equity indexes continued their autumn rally, and there could be more gains before the end of the year, helped by conti...
Moderna Stock Takes Off on Cancer Vaccine News
Moderna stock shot up after Merck said it is exercising an option to work on a personalized cancer vaccine with the Covid-19 vaccine maker. Merck (ticker: MRK) will pay Moderna (MRNA) $250 million for...
10 defensive stocks that can also provide you with growth and dividends over the long term
The S&P 500 Index has rallied 10% since June 22 from a deep decline, but there are different schools of thought about whether investors are out of the woods yet. Mark Hulbert has called the recent...
Pfizer in Advanced Talks to Buy Global Blood Therapeutics for About $5 Billion
Pfizer is in advanced talks to buy Global Blood Therapeutics the maker of a recently approved drug for sickle-cell disease, for about $5 billion, in the latest move by the drug giant to bolster its po...
Merck Is Now in Advanced Talks to Buy Cancer Biotech Seagen for $40 Billion
Text size New Jersey-based Merck has a market value of more than $234 billion. Michael Vi/Dreamstime Merck & Co is in advanced talks to buy Seagen in a deal that could value the cancer biotech at...
Merck Is in Advanced Talks to Buy Seagen for Roughly $40 Billion or More
Merck & Co. is in advanced talks to acquire Seagen and is aiming to agree on a purchase of the cancer biotech in the next few weeks, according to people familiar with the matter, in a deal that co...
Merck Pushes Forward With Potential Deal for Seagen
Merck & Co. is pushing forward with a potential deal for biotech Seagen Inc., according to people familiar with the matter, in what would be one of the largest takeovers of the year. The Wall Stre...
Stocks Are Ready for a Bounce Higher After S&P 500 Closes Above Bear Market
Text size Dreamstime The stock market came awfully close to finishing Friday in a bear market, at least 20% off its peak in early January. Many investors would like to see it get there so Wall Street ...
Big Pharma Has Enough Cash to Buy All of Biotech. Why M&A Isn’t Happening.
Text size Late last year, Barron’s predicted a wave of deals, citing biotech companies’ cash holdings. Above, the plates used to print one-dollar bills. Alex Wong/Getty Images With biotech...
Merck (MRK) earnings Q1 2022
Medicine pill is seen with Merck logo and words ‘Molnupiravir’ and ‘COVID-19’ displayed on a screen in the background in this illustration photo taken in Poland on November 5, ...
Merck (MRK) earnings Q4 2021
Merck sold $952 million of its Covid-19 treatment pill molnupiravir in the fourth quarter, saying Thursday it’s on track to sell another $5 billion to $6 billion more this year. Most of its sale...
Genprex stock more than doubles on very heavy volume after FTD granted for cancer treatment
Shares of Genprex Inc. GNPX, +167.18% skyrocketed 121% on massive volume in afternoon trading Monday, after the gene therapy company said its Reqorsa Immunogene Therapy was granted Fast Track Designat...
Intel’s dividend cut shows the need for quality. Here are 20 dividend stocks screened by UBS.
Stocks that pay high dividends can provide comfort during times of market turmoil. It is much easier to be patient if money is rolling in, and a strategy of reinvesting dividends may outperform when t...